| 39.34 Data as of May 24 |  -0.15 / -0.38%Today’s Change | 36.63 Today|||52-Week Range 42.83 | +5.36% Year-to-Date |
| Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) May 21 / TheStreet.com | Teva - Alexza Sign Deal for Adasuve - Analyst Blog May 13 / Zacks.com |
| Ireland Welcomes Watson Pharmaceuticals, an American Success May 20 / TheStreet.com | Actavis: What it's like to join the Fortune 500 May 10 / Fortune |
| Previous close | 39.49 |
| Today’s open | 39.50 |
| Day’s range | 38.89 - 39.55 |
| Volume | 3,354,591 |
| Average volume (3 months) | 4,115,236 |
| Market cap | $37.3B |
| Dividend yield | 2.87% |
| Earnings growth (last year) | -27.16% |
| Earnings growth (this year) | -6.13% |
| Earnings growth (next 5 years) | +3.80% |
| Revenue growth (last year) | +11.34% |
| P/E ratio | 14.2 |
| Price/Sales | 1.60 |
| Price/Book | 1.49 |
| Today’s change | Today’s % change | |
|---|---|---|
| NEPTNeptune Technologies... | -0.09 | -3.16% |
| Next reporting date | July 30, 2013 |
| EPS forecast (this quarter) | $1.20 |
| Annual revenue (last year) | $20.3B |
| Annual profit (last year) | $2.0B |
| Net profit margin | 9.66% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
President & Chief Executive Officer Jeremy M. Levin, PhD |
President & CEO-Global Operations Carlo de Notaristefani, PhD |
Corporate headquarters Petach Tikva, -- |
.
